Literature DB >> 3425656

Fetal umbilical artery flow velocimetry in postdate pregnancies.

D A Guidetti1, M Y Divon, R L Cavalieri, O Langer, I R Merkatz.   

Abstract

This study prospectively examined the use of umbilical artery flow velocimetry for monitoring fetal health in postdate pregnancies. Forty-six patients with well-established dates were evaluated with semiweekly biophysical profiles and umbilical artery flow velocimetry (characterized by the ratio of the peak systolic to end-diastolic velocity). Their labor records were reviewed, and neonates were examined for signs of postmaturity. Twenty neonates had an abnormal test result or outcome (identified as an abnormal nonstress test, oligohydramnios, meconium, intrapartum fetal distress, or a 5-minute Apgar score less than 7). Nine neonates had a physical examination consistent with the postmaturity syndrome. Twenty-one neonates were entirely normal. Comparisons of the mean systolic/diastolic ratios for neonates with and without the complications associated with postdatism showed no significant differences. In addition, all systolic/diastolic ratios were within the normal range. Therefore, umbilical artery flow velocimetry is unlikely to be useful for the routine antenatal assessment of the postdate fetus.

Entities:  

Mesh:

Year:  1987        PMID: 3425656     DOI: 10.1016/s0002-9378(87)80255-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  Aging of the placenta.

Authors:  H Fox
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-11       Impact factor: 5.747

Review 2.  Postterm pregnancy.

Authors:  M Galal; I Symonds; H Murray; F Petraglia; R Smith
Journal:  Facts Views Vis Obgyn       Date:  2012

3.  Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop.

Authors:  Caroline Signore; Roger K Freeman; Catherine Y Spong
Journal:  Obstet Gynecol       Date:  2009-03       Impact factor: 7.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.